Public Employees Retirement System of Ohio Purchases New Shares in Qiagen N.V. $QGEN

Public Employees Retirement System of Ohio purchased a new position in shares of Qiagen N.V. (NYSE:QGEN) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 72,503 shares of the company’s stock, valued at approximately $2,836,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Boston Partners purchased a new stake in shares of Qiagen in the third quarter valued at about $179,450,000. Norges Bank purchased a new position in shares of Qiagen during the fourth quarter worth about $166,500,000. Dimensional Fund Advisors LP acquired a new position in Qiagen in the 3rd quarter valued at about $58,079,000. Price T Rowe Associates Inc. MD raised its stake in Qiagen by 12.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 8,429,424 shares of the company’s stock valued at $379,072,000 after acquiring an additional 906,589 shares during the last quarter. Finally, Deutsche Bank AG raised its stake in Qiagen by 9.7% during the 4th quarter. Deutsche Bank AG now owns 7,907,801 shares of the company’s stock valued at $355,614,000 after acquiring an additional 697,342 shares during the last quarter. 70.00% of the stock is owned by hedge funds and other institutional investors.

Qiagen Stock Performance

NYSE QGEN opened at $43.36 on Friday. The business has a 50 day moving average price of $41.91 and a 200 day moving average price of $40.41. The company has a market capitalization of $8.94 billion, a P/E ratio of 22.22, a PEG ratio of 4.33 and a beta of 0.63. Qiagen N.V. has a 1-year low of $32.53 and a 1-year high of $57.81. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.85 and a quick ratio of 2.31.

Qiagen (NYSE:QGEN) last posted its earnings results on Wednesday, August 5th. The company reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.60 by $0.02. Qiagen had a return on equity of 14.47% and a net margin of 19.49%.The company had revenue of $535.04 million for the quarter, compared to analyst estimates of $527.50 million. During the same quarter in the prior year, the company earned $0.60 earnings per share. Qiagen’s revenue was up .2% compared to the same quarter last year. Qiagen has set its FY 2026 guidance at 2.430- EPS. Sell-side analysts expect that Qiagen N.V. will post 2.43 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

QGEN has been the subject of several analyst reports. TD Cowen restated a “hold” rating on shares of Qiagen in a research note on Wednesday, July 15th. Kepler Capital Markets set a $38.60 price objective on shares of Qiagen and gave the company a “hold” rating in a research report on Thursday, June 25th. JPMorgan Chase & Co. boosted their price objective on shares of Qiagen from $45.00 to $50.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Berenberg Bank set a $45.50 price objective on shares of Qiagen and gave the stock a “hold” rating in a research report on Tuesday, July 14th. Finally, Weiss Ratings upgraded shares of Qiagen from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, August 17th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat, Qiagen has a consensus rating of “Hold” and a consensus price target of $43.93.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library?preparation kits and proteomics solutions.